PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2024Journal of Clinical Oncology2 citations

Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

View Full Paper

Authors

ZLZhiyong LiSouth China Agricultural UniversityLHLiru HeSun Yat-sen UniversityKYKai YaoSun Yat-sen University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e66c53b6db6435875f71cbhttps://doi.org/10.1200/jco.2024.42.16_suppl.e16600
Ask AI
Helpful
Bookmark
Share
View Full Paper